Results 271 to 280 of about 192,321 (311)

PPreclinical Evaluation of Drugs for Evidence of Teratogenic Activity

Journal of Pharmaceutical Sciences, 1963
“If certain congenital malformations can be attributed in certain animals to dietary deficiency, anoxia, cortisone, or genetic constellations, one must not conclude without further proof that comparable malformations in man are due to similar adverse conditions.
openaire   +2 more sources

Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials

Nature Reviews Drug Discovery, 2021
David Langenau, E Elizabeth Patton, Leonard Zon   +2 more
exaly  

Extracellular vesicles as a drug delivery system: A systematic review of preclinical studies

Advanced Drug Delivery Reviews, 2021
Jiong-Wei Wang, Lingjun Tong, Raymond Schiffelers   +2 more
exaly  

A Postgraduate Course in Preclinical Drug Evaluation

Therapies, 2004
openaire   +2 more sources

Significance of neurochemical parameters in the preclinical evaluation of neuroleptic drugs

Pharmacology & Therapeutics, 1979
F, Cattabeni, C L, Galli, A, Groppetti, G, Racagni   +3 more
openaire   +2 more sources

Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction

Acta Pharmaceutica Sinica B, 2021
Maria Isabel Lucena Gonzalez, , Eduardo García-Fuentes   +2 more
exaly  

[Preclinical/toxicologic evaluation of drugs].

Ugeskrift for laeger, 1999
Knudsen, Lisbeth E., Spindler, Per, Renneberg, Jan   +2 more
openaire   +1 more source

Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment

Antimicrobial Agents and Chemotherapy, 2022
James Mccarthy, Joerg Moehrle, Matthias Rottmann   +2 more
exaly  

Preclinical Drug Safety Evaluation

2008
openaire   +1 more source

Preclinical Drug Safety Evaluation

2011
openaire   +1 more source